

Early and locally advanced breast cancer (update) Committee meeting 8

Date: 14 and 15 September 2017

Location: RCOG, London

Minutes: Confirmed

Committee members present:		
Jane Barrett (Chair)		(Present for items 1 – 8)
Anne Armstrong (Topic Advisor)		(Present for items 1 – 8)
Faye Coe		(Present for items 1 – 8)
Ramsey Cutress		(Present for items 6 – 8)
Sadaf Haque		(Present for items 6 – 8)
Roger Hunt		(Present for items 1 – 5)
Peter Jenkins		(Present for items 6 – 8)
Imogen Locke		(Present for items 1 – 8)
Marina Parton		(Present for items 1 – 8)
Linda Pepper		(Present for items 1 – 8)
Mia Rosenblatt		(Present for items 1 – 8)
William Teh		(Present for items 1 – 5)
Ursula Van Mann		(Present for items 1 – 8)
Lisa Whisker		(Present for items 1 – 8)
Sairanne Wickers		(Present for items 1 – 8)

In attendance:		
Andrew Harding	NICE Guideline Commissioning Manager	(Present for items 1 – 5)
Hilary Eadon	NGA Guideline Lead	(Present for items 1 – 8)
John Graham	NGA Clinical Advisor	(Present for items 6 – 8)
Sally Humphreys	NGA Project Manager	(Present for items 1 – 8)
Fionnuala O'Brien	NGA Project Manager	(Present for item 4)
Laura O'Shea	NGA Systematic Reviewer	(Present for items 1 – 8)
Anuja Pandey	NGA Systematic Reviewer	(Present for items 1 – 8)
Matthew Prettyjohns	NGA Senior Health Economist	(Present for items 1 – 5)
Gemma Villanueva	NGA Senior Systematic Reviewer	(Present for items 1 – 8)

Apologies:		
Ramsey Cuttress	GC member	(Absent for items 1 – 5)
Carmel Gulliver-Clarke	GC member	(Absent for items 1 – 8)
Sadaf Haque	GC member	(Absent for items 1 – 5)
Roger Hunt	GC member	(Absent for items 6 – 8)
Peter Jenkins	GC member	(Absent for items 1 – 5)
William Teh	GC member	(Absent for items 6 – 8)
Andrew Harding	NICE Guideline Commissioning Manager	(Absent for items 1 – 5)
Sarah Palombella	NICE Senior Medical Editor	(Absent for items 1 – 8)
Joanna Perkin	NICE Digital Editor	(Absent for items 1 – 8)
John Graham	NGA Clinical Advisor	(Absent for items 1 – 5)
Matthew Prettyjohns	NGA Senior Health Economist	(Absent for items 6 – 8)

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 8th meeting on Early and locally advanced breast cancer (update).

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting which included reviewing the evidence and drafting recommendations for questions 7.1, 9.1, 10.4, 9.2 and 10.5, reviewing the draft economic model for question 6.1, and considering the NICE editor's proposed wording amendments to the recommendations drafted to date, and refreshing recommendations for areas which are not being reviewed as part of this guideline update.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Early and locally advanced breast cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken

<p>Anne Armstrong</p>	<p>Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust</p>	<p>14.9.2017 Local Principal Investigator: PIPA: A Phase 1b study to assess the safety, tolerability and activity of the PI3K inhibitor taselesib (GDC-0032), in combination with Palbociclib, with the subsequent addition of fulvestrant in PIK3CA-mutant breast cancers or letrozole in advanced breast cancers. Sponsor: Royal Marsden.</p>	<p>Non-personal financial, non-specific</p>	<p>Declare and continue</p>
<p>Anne Armstrong</p>	<p>Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust</p>	<p>UK Co-ordinating investigator: AIPAC (Active Immunotherapy PAClitaxel): A multicentre, Phase IIb, randomised double blind, placebo controlled study in hormone</p>	<p>Non-personal financial, non-specific</p>	<p>Declare and continue</p>

		receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-31g fusion protein) or placebo as adjunctive to a standard chemotherapy treatment regimen of paclitaxel. Sponsor: Immunetp SAS		
Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	14.9.2017 Local Principal Investigator: A Phase 3 open-label, randomized, multicentre study of NKTR-102 versus treatment of physician's choice (TPC) in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane,	Non-personal financial, non-specific	Declare and continue

		and capecitabine. Sponsor: Nektar Therapeutics		
<p>Due to a potential conflict of interests Anne Armstrong withdrew from discussion on the evidence review for question 10.4.</p>				
<p>3. Minutes of last meeting</p>				
<p>The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.</p>				
<p>4. Day 1 presentations</p>				
<p>The Chair introduced Laura O'Shea, NGA Systematic Reviewer, who gave a presentation on the evidence for RQ7.1 What are the indications for using adjuvant bisphosphonates in people with early and locally advanced breast cancer?</p> <p>The Chair introduced Gemma Villanueva, NGA Senior Systematic Reviewer, who gave a presentation on the evidence for question 9.1 What are the indications for post mastectomy radiotherapy for people with early and locally advanced breast cancer?</p> <p>The Chair introduced Matthew Prettyjohns, NGA Senior Health Economist, who gave a presentation on the economic model for RQ6.1 Which people with T1 N0 human epidermal growth receptor 2 (HER2)-positive breast cancers benefit from adjuvant trastuzumab in combination with chemotherapy?</p> <p>The Chair introduced Laura O'Shea, NGA Systematic Reviewer, who gave a presentation on the evidence for RQ10.4 What is the role of chemoprevention in women following initial treatment for ductal carcinoma in situ (DCIS)?</p> <p>The Chair introduced Laura O'Shea, NGA Systematic Reviewer, who discussed the review questions where it was necessary to conduct re-run searches.</p> <p>The speakers took questions from the group. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked the speakers for their presentations.</p>				
<p>5. Day 1 questions and discussion</p>				
<p>The Committee discussed the evidence for review questions and agreed</p>				

recommendations and content for the sections linking the evidence to recommendations.

The Committee discussed the results of the economic model for question 6.1 and reviewed the recommendations for this topic.

6. Day 2 presentations

The Chair introduced Anuja Pandey, NGA Systematic Reviewer, who gave a presentation on the evidence for RQ10.5 Do people with triple negative or BRCA germ line mutation with early and locally advanced breast cancer benefit from the addition of a platinum to standard neo-adjuvant chemotherapy?

The Chair introduced Hilary Eadon, NGA Guideline Lead, who led a review of the recommendations developed to date following editing by the NICE Senior Medical Editor.

The Chair introduced Laura O'Shea who gave a presentation on the evidence for RQ9.2 Should the potential need for radiotherapy preclude immediate breast reconstruction?

The Chair introduced Hilary Eadon, NGA Guideline Lead, who led a review of the research recommendations developed to date.

The Chair introduced Hilary Eadon, NGA Guideline Lead, who led a review of the recommendations from CG80 in areas where evidence is not being updated.

The speakers took questions from the group. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked the speakers for their presentations.

7. Day 2 questions and discussion

The Committee discussed the evidence for review questions and agreed recommendations and content for the sections linking evidence to recommendations.

The Committee then reviewed the NICE editor's comments on the recommendations that had been drafted previously and on the refreshed language of the recommendations which were not being updated.

8. Any other business

The GC was informed that NICE has published a new evidence summary on bisphosphonates in early breast cancer

Date of next meeting: 9 October 2017

Location of next meeting: RCOG, London